Attached files
| file | filename |
|---|---|
| 10-K - FORM 10-K - ALNYLAM PHARMACEUTICALS, INC. | d835246d10k.htm |
| EX-12 - EX-12 - ALNYLAM PHARMACEUTICALS, INC. | d835246dex12.htm |
| EX-21.1 - EX-21.1 - ALNYLAM PHARMACEUTICALS, INC. | d835246dex211.htm |
| EXCEL - IDEA: XBRL DOCUMENT - ALNYLAM PHARMACEUTICALS, INC. | Financial_Report.xls |
| EX-32.1 - EX-32.1 - ALNYLAM PHARMACEUTICALS, INC. | d835246dex321.htm |
| EX-32.2 - EX-32.2 - ALNYLAM PHARMACEUTICALS, INC. | d835246dex322.htm |
| EX-31.2 - EX-31.2 - ALNYLAM PHARMACEUTICALS, INC. | d835246dex312.htm |
| EX-31.1 - EX-31.1 - ALNYLAM PHARMACEUTICALS, INC. | d835246dex311.htm |
EXHIBIT 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statement on Form S-3 (Nos. 333-185658, 333-138586, 333-131233, 333-129905, 333-140076 and 333-175694) and S-8 (Nos. 333-190498, 333-127450, 333-116151, 333-148114, 333-157633, 333-165105 and 333-172370) of Alnylam Pharmaceuticals, Inc. of our report dated February 13, 2015 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 10-K.
/s/ PricewaterhouseCoopers LLP
Boston, Massachusetts
February 13, 2015